AKT1 and Parkinson disease: An in vivo study found that the inhibition of the PI3K/Akt/mTOR signaling pathway led to a decrease in the expression of c-Jun N-terminal kinase-p53-Bax 3(JNK3), thus protecting dopaminergic neurons and improving Parkinson’s disease (Chen Y. et al., 2018).